Daunorubicin citrate
Based on 43 publication(s) in Google Scholar
Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
For research use only. We do not sell to patients.
- CAS No.: 1884557-85-0
- Formula: C33H37NO17
- Molecular Weight:719.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Daunorubicin citrate
More- Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
- Cancer Res. 2024 Feb 1;84(3):479-492. [Abstract]
- ACS Nano. 2024 Nov 12;18(45):31569-31585. [Abstract]
- J Adv Res. 2025 May 21:S2090-1232(25)00358-3. [Abstract]
- Interdiscip Med. 2025 Sep 1;3(5):e70053.
- Cell Rep Med. 2026 Jan 20;7(1):102542. [Abstract]
- Sci Adv. 2026 Apr 3;12(14):eady4536. [Abstract]
- J Control Release. 2022 Apr 22;346:136-147. [Abstract]
- Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. [Abstract]
- J Transl Med. 2022 Jul 6;20(1):304. [Abstract]
- Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]
- EMBO Mol Med. 2025 Nov 26. [Abstract]
- Cell Prolif. 2026 Jun 16:e70250. [Abstract]
- Pharmaceutics. 2021 May 5;13(5):661. [Abstract]
- Biochem Pharmacol. 2026 Aug;250(Pt 1):117991. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- Life Sci. 2025 Jan 15:361:123297. [Abstract]
- RSC Adv. 2026 Apr 7;16(20):18359-18373. [Abstract]
- Cancer Biol Ther. 2020 Apr 2;21(4):320-331. [Abstract]
- Int J Mol Sci. 2026 Mar 11;27(6):2587. [Abstract]
- Cell Oncol (Dordr). 2022 Oct;45(5):1005-1018. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
- Cancers (Basel). 2021 Mar 5;13(5):1127. [Abstract]
- Cell Signal. 2025 Jul:131:111735. [Abstract]
- Cell Signal. 2025 Apr:128:111625. [Abstract]
- Mol Cell Biochem. 2021 Feb;476(2):1233-1243. [Abstract]
- ACS Infect Dis. 2022 Aug 12;8(8):1618-1626. [Abstract]
- J Antimicrob Chemother. 2025 Sep 3;80(9):2447-2458. [Abstract]
- Front Biosci (Landmark Ed). 2024 Oct 21;29(10):362. [Abstract]
- Curr Pharm Anal. 2018 Jan, 14(1):53-59(7).
- Front Oncol. 2021 Apr 22:11:665763. [Abstract]
- Front Genet. 2021 Aug 5:12:678368. [Abstract]
- Ann Hematol. 2026 May 29. [Abstract]
- Oncol Lett. 2020 Jan;19(1):368-378. [Abstract]
- Microb Drug Resist. 2020 Jan;26(1):81-88. [Abstract]
- Res Sq. 2026 Jun 18:rs.3.rs-9901177. [Abstract]
- bioRxiv. 2026 Feb 3.
- Biomed Pharmacother. 2025 Jun:187:118104. [Abstract]
- Patent. US20240319170A1
- bioRxiv. 2024 July 04.
- Universidad De Salamanca. 2023
- bioRxiv. 2023 Jan 13.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
All Topoisomerase Isoforms
MoreAll DNA/RNA Synthesis Isoforms
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Topoisomerase II |
Daunorubicins/Doxorubicins |
Daunorubicin citrate (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2].
Daunorubicin citrate (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4].
Daunorubicin citrate (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4].
Daunorubicin citrate (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4].
Daunorubicin citrate (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
-
Concentration:7 nM-1.9 μM
-
Incubation Time:72 h
-
Result:Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6).
-
Cell Line:L3.6 cells
-
Concentration:0.4 μM
-
Incubation Time:24 h, 48 h
-
Result:Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.
-
Cell Line:K562 cells
-
Concentration:2 μM
-
Incubation Time:24 h
-
Result:Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.
Daunorubicin citrate (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats[5]
-
Dosage:3 mg/kg
-
Administration:Intravenous injection, three times at 48 h intervals.
-
Result:Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
Increased urinary protein excretion, serum creatinine, and BUN level.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1884557-85-0
-
Molecular Weight 719.64
-
Formula C33H37NO17
-
SMILES
OC(C(O)=O)(CC(O)=O)CC(O)=O.OC1=C2C([C@H](C[C@@](C(C)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)N)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O
-
Synonyms
Daunomycincitrate; RP 13057citrate; Rubidomycincitrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (43)
-
Journal Impact Factor
-
Most Recent
-
Cell Mol Immunol
Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]2023 Jan;20(1):51-64. PMID: 36447031
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
-
Cancer Res
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]2024 Feb 1;84(3):479-492. PMID: 38095536 -
ACS Nano
Unveiling the Heart's Hidden Enemy: Dynamic Insights into Polystyrene Nanoplastic-Induced Cardiotoxicity Based on Cardiac Organoid-on-a-Chip. [Abstract]2024 Nov 12;18(45):31569-31585. PMID: 39482939 -
J Adv Res
Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. [Abstract]2025 May 21:S2090-1232(25)00358-3. PMID: 40409464 -
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.
Cell viability analysis of OCI-AML2 cells expressing the indicated sgRNAs following treatment with increasing concentrations of Daunorubicin hydrochloride (3 days), assessed using the CCK-8 assay.
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.
OCI-AML2 cells expressing indicated sgRNAs were treated with DMSO or Daunorubicin hydrochloride (10 nM), and viable cells were counted every 3–4 days.
-
Cell Rep Med
2026 Jan 20;7(1):102542. PMID: 41564858 -
Sci Adv
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma. [Abstract]2026 Apr 3;12(14):eady4536. PMID: 41920996 -
J Control Release
Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC. [Abstract]2022 Apr 22;346:136-147. PMID: 35447298 -
Clin Cancer Res
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]2020 Apr 15;26(8):2011-2021. PMID: 31937620 -
J Transl Med
2022 Jul 6;20(1):304. PMID: 35794581
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304. [Abstract]
IC50 curves of Daunorubicin hydrochloride (1.25-1280 nM; 48 h) in U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control. Transduced AML cells were treated with daunorubicin for 48 h and then measured by CCK-8 analysis.
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304. [Abstract]
Cell apoptosis rate of U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control after Daunorubicin hydrochloride (10-80 nM) treatment was detected by flow cytometry using Annexin V-APC /PI staining.
-
Leukemia
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]2023 Jun;37(6):1336-1348. PMID: 36977823 -
EMBO Mol Med
Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]2025 Nov 26. PMID: 41299101 -
Cell Prolif
2026 Jun 16:e70250. PMID: 42303242 -
Pharmaceutics
Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. [Abstract]2021 May 5;13(5):661. PMID: 34063098
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661. [Abstract]
Primary AML cells were treated with Daunorubicin hydrochloride (DNR, 8-32 μM) and Erastin (5 μM) for 48 h, and cell viability was assessed using the CCK-8 assay.
Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661. [Abstract]
HL-60 cells were pretreated with CCL20 for 30 min, followed by Daunorubicin hydrochloride (DNR, 1.6, 3.2 μM) treatment for 48 h, and lipid peroxidation level were measured.
-
Biochem Pharmacol
Pharmacologic modulation of the SAT1-N1-acetylspermidine axis is associated with enhanced chemotherapy cytotoxicity in T-LBL/ALL cells. [Abstract]2026 Aug;250(Pt 1):117991. PMID: 42002236 -
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
Life Sci
M2 macrophages secrete CCL20 to regulate iron metabolism and promote daunorubicin resistance in AML cells. [Abstract]2025 Jan 15:361:123297. PMID: 39645162 -
RSC Adv
A multi-stage computational pipeline and in vitro validation for the discovery of small-molecule translation inhibitors targeting the bacterial ribosome. [Abstract]2026 Apr 7;16(20):18359-18373. PMID: 41953617 -
Cancer Biol Ther
SIRT6-PARP1 is involved in HMGB1 polyADP-ribosylation and acetylation and promotes chemotherapy-induced autophagy in leukemia. [Abstract]2020 Apr 2;21(4):320-331. PMID: 31928132 -
Int J Mol Sci
2026 Mar 11;27(6):2587. PMID: 41898448 -
Cell Oncol (Dordr)
Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines. [Abstract]2022 Oct;45(5):1005-1018. PMID: 36036884 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Cancers (Basel)
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]2022 Oct 19;14(20):5127. PMID: 36291909 -
Cancers (Basel)
Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. [Abstract]2021 Mar 5;13(5):1127. PMID: 33807974 -
Cell Signal
OTUB1 promotes the progression of acute myeloid leukemia by regulating glycolysis via deubiquitinating c-Myc. [Abstract]2025 Jul:131:111735. PMID: 40081551 -
Cell Signal
LncRNA SNHG5 induces CAFs-like phenotype and autophagy of AML-MSCs via PTBP1/ATG5 axis to confer chemoresistance of AML cells. [Abstract]2025 Apr:128:111625. PMID: 39864537 -
Mol Cell Biochem
RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. [Abstract]2021 Feb;476(2):1233-1243. PMID: 33247805 -
ACS Infect Dis
Tea Tree Oil Nanoemulsion Potentiates Antibiotics against Multidrug-Resistant Escherichia coli. [Abstract]2022 Aug 12;8(8):1618-1626. PMID: 35854664 -
J Antimicrob Chemother
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo. [Abstract]2025 Sep 3;80(9):2447-2458. PMID: 40711771 -
Front Biosci (Landmark Ed)
GRK2 Protein Mediates the ANRIL, a lncRNA, to Affect the Proliferation and Apoptosis of Kasumi-1 Cells. [Abstract]2024 Oct 21;29(10):362. PMID: 39473411 -
-
Front Oncol
2021 Apr 22:11:665763. PMID: 33968771 -
Front Genet
2021 Aug 5:12:678368. PMID: 34421991 -
Ann Hematol
Identification and validation of a prognostic risk-scoring model in drug-resistant ALL and evaluation of immune micro-environment. [Abstract]2026 May 29. PMID: 42215742 -
Oncol Lett
Poly (ADP-ribosylation) of HMGB1 facilitates its acetylation and promotes HMGB1 translocation-associated chemotherapy-induced autophagy in leukaemia cells. [Abstract]2020 Jan;19(1):368-378. PMID: 31897149 -
Microb Drug Resist
Synergistic Activity of Fluoroquinolones Combining with Artesunate Against Multidrug-Resistant Escherichia coli. [Abstract]2020 Jan;26(1):81-88. PMID: 31738637 -
Res Sq
2026 Jun 18:rs.3.rs-9901177. PMID: 42370261 -
-
Biomed Pharmacother
Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]2025 Jun:187:118104. PMID: 40300391 -
-
-
-
Purity & Documentation
References
[1]. Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. [Content Brief]
[2]. Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14. [Content Brief]
[3]. Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4. [Content Brief]
[4]. Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26. h [Content Brief]
[5]. Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9. [Content Brief]
[6]. Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. [Content Brief]
[7]. Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Daunorubicin citrate Related Classifications
HY-108876 Related Classifications
Powered by Bioz